Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Gliosarcoma 2Glioma 2Glioblastoma 2Brain Neoplasms 2Medulloblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Magnetic Resonance Spectroscopy 15Temozolomide 14Radiotherapy 6Filgrastim 6Carmustine 6Biopsy 6X-Rays 5Phantoms, Imaging 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5sargramostim 4Specimen Handling 4Peripheral Blood Stem Cell Transplantation 4Nuclear Medicine Department, Hospital 4Cyclophosphamide 4olaparib 3Thiotepa 3Gadolinium DTPA 3Cisplatin 3Carboplatin 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2larotrectinib 2ivosidenib 2fluorodopa F 18 2ensartinib 2aldesleukin 2Yoga 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × 1-methyltryptophan × Sarcoma × Clear all
NCT02502708 2020-06-04

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Lumos Pharma

Phase 1 Completed
81 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡